

HR 1699

Patient Access to Critical Lab Tests Act

Congress: 111 (2009–2011, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 25, 2009

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 26, 2009)

Official Text: <https://www.congress.gov/bill/111th-congress/house-bill/1699>

Sponsor

Name: Rep. Altmire, Jason [D-PA-4]

Party: Democratic • State: PA • Chamber: House

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Eshoo, Anna G. [D-CA-14]	D · CA		Mar 25, 2009
Rep. Murphy, Tim [R-PA-18]	R · PA		Mar 25, 2009
Rep. Doyle, Michael F. [D-PA-14]	D · PA		Apr 21, 2009
Rep. Roybal-Allard, Lucille [D-CA-34]	D · CA		May 21, 2009
Rep. Sestak, Joe [D-PA-7]	D · PA		Sep 30, 2009

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 26, 2009
Ways and Means Committee	House	Referred To	Mar 25, 2009

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
111 S 1220	Related bill	Jun 9, 2009: Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S6383)

Patient Access to Critical Lab Tests Act - Expresses the sense of Congress that: (1) where practical, Medicare regulations and policies should be written to promote development of and access to certain highly specialized laboratory tests; and (2) certain Medicare regulations should be revised to permit laboratories furnishing such tests to bill for and be paid directly by Medicare for furnishing them.

Declares that, whenever a laboratory performs a covered complex diagnostic laboratory test, with respect to a specimen collected from an individual during a period in which the individual is a hospital patient, if the test is performed after such period, the Secretary of Health and Human Services shall treat such test, for purposes of making direct payment to the laboratory, as if the specimen had been collected by the laboratory directly.

Defines "covered complex diagnostic laboratory test" as: (1) an analysis of DNA, RNA, chromosomes, proteins, or metabolites that detects genotypes, mutations, chromosomal changes, biochemical changes, cell response, or gene expression or is a cancer chemotherapy sensitivity assay, with certain exceptions; (2) a diagnostic X-ray or other diagnostic test; (3) one developed and performed by a laboratory independent of the hospital in which the specimen involved was collected, and not under any arrangements with such hospital; and (4) one not furnished by such hospital, directly or under any arrangements made by it.

Actions Timeline

- **Mar 26, 2009:** Referred to the Subcommittee on Health.
- **Mar 25, 2009:** Introduced in House
- **Mar 25, 2009:** Referred to House Energy and Commerce
- **Mar 25, 2009:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Mar 25, 2009:** Referred to House Ways and Means